PBMs’ Evolving Business Model Continues To Raise Costs On Patients
NegativeFinancial Markets

- The business model of Pharmacy Benefit Managers (PBMs) is increasingly raising drug costs for patients, necessitating reforms in the PBM market. These reforms should specifically target the growing use of group purchasing organizations (GPOs) by PBMs, which is believed to be a contributing factor to the rising expenses faced by patients.
- The implications of this development are significant, as addressing the practices of PBMs could lead to lower drug prices for consumers. Without reform, patients may continue to face high costs for medications, highlighting the urgent need for regulatory changes in the pharmaceutical supply chain.
— via World Pulse Now AI Editorial System







